{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:46:31Z","timestamp":1787060791518,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T00:00:00Z","timestamp":1686182400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s00108-023-01529-7","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T16:35:25Z","timestamp":1686242125000},"page":"642-648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Das polyzystische Ovarsyndrom als genderspezifischer kardiometabolischer Risikofaktor","Polycystic ovary syndrome as a gender-specific cardiometabolic risk factor"],"prefix":"10.1007","volume":"64","author":[{"given":"Lukas","family":"van Baal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,8]]},"reference":[{"key":"1529_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12958-020-00576-1","volume":"18","author":"M Amiri","year":"2020","unstructured":"Amiri\u00a0M, Ramezani Tehrani\u00a0F, Behboudi-Gandevani\u00a0S, Bidhendi-Yarandi\u00a0R, Carmina\u00a0E (2020) Risk of hypertension in women with polycystic ovary syndrome: a\u00a0systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol 18:23","journal-title":"Reprod Biol Endocrinol"},{"key":"1529_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/cen.13477","volume":"88","author":"S Behboudi-Gandevani","year":"2018","unstructured":"Behboudi-Gandevani\u00a0S, Amiri\u00a0M, Bidhendi Yarandi\u00a0R, Noroozzadeh\u00a0M, Farahmand\u00a0M, Rostami Dovom\u00a0M, Ramezani Tehrani\u00a0F (2018) The risk of metabolic syndrome in polycystic ovary syndrome: A systematic review and meta-analysis. Clin Endocrinol (Oxf) 88:169\u2013184","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1529_CR3","doi-asserted-by":"publisher","first-page":"e3369","DOI":"10.1210\/clinem\/dgab392","volume":"106","author":"TR Berni","year":"2021","unstructured":"Berni\u00a0TR, Morgan\u00a0CL, Rees\u00a0DA (2021) Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a\u00a0population study. J\u00a0Clin Endocrinol Metab 106:e3369\u2013e3380","journal-title":"J Clin Endocrinol Metab"},{"key":"1529_CR4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/humrep\/dey343","volume":"34","author":"MA Brower","year":"2019","unstructured":"Brower\u00a0MA, Hai\u00a0Y, Jones\u00a0MR, Guo\u00a0X, Chen\u00a0YI, Rotter\u00a0JI, Krauss\u00a0RM, Legro\u00a0RS, Azziz\u00a0R, Goodarzi\u00a0MO (2019) Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Hum Reprod 34:127\u2013136","journal-title":"Hum Reprod"},{"key":"1529_CR5","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1093\/humrep\/deg440","volume":"18","author":"E Carmina","year":"2003","unstructured":"Carmina\u00a0E, Legro\u00a0RS, Stamets\u00a0K, Lowell\u00a0J, Lobo\u00a0RA (2003) Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 18:2289\u20132293","journal-title":"Hum Reprod"},{"key":"1529_CR6","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1093\/humrep\/dew243","volume":"31","author":"S Cassar","year":"2016","unstructured":"Cassar\u00a0S, Misso\u00a0ML, Hopkins\u00a0WG, Shaw\u00a0CS, Teede\u00a0HJ, Stepto\u00a0NK (2016) Insulin resistance in polycystic ovary syndrome: a\u00a0systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod 31:2619\u20132631","journal-title":"Hum Reprod"},{"key":"1529_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrendo.2018.24","volume":"14","author":"HF Escobar-Morreale","year":"2018","unstructured":"Escobar-Morreale\u00a0HF (2018) Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol 14:270\u2013284","journal-title":"Nat Rev Endocrinol"},{"key":"1529_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1210\/clinem\/dgab658","volume":"107","author":"C Falzarano","year":"2022","unstructured":"Falzarano\u00a0C, Lofton\u00a0T, Osei-Ntansah\u00a0A, Oliver\u00a0T, Southward\u00a0T, Stewart\u00a0S, Andrisse\u00a0S (2022) Nonalcoholic fatty liver disease in women and girls with polycystic ovary syndrome. J\u00a0Clin Endocrinol Metab 107:258\u2013272","journal-title":"J Clin Endocrinol Metab"},{"key":"1529_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1093\/humrep\/deac267","volume":"38","author":"CL Haas","year":"2023","unstructured":"Haas\u00a0CL, Varbo\u00a0A, Laursen\u00a0PN, Schnecke\u00a0V, Balen\u00a0AH (2023) Association between body mass index, weight loss and the chance of pregnancy in women with polycystic ovary syndrome and overweight or obesity: a\u00a0retrospective cohort study in the UK. Hum Reprod 38:471\u2013481","journal-title":"Hum Reprod"},{"key":"1529_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1055\/s-2005-870236","volume":"37","author":"S Hahn","year":"2005","unstructured":"Hahn\u00a0S, Tan\u00a0S, Elsenbruch\u00a0S, Quadbeck\u00a0B, Herrmann\u00a0BL, Mann\u00a0K, Janssen\u00a0OE (2005) Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm Metab Res 37:438\u2013444","journal-title":"Horm Metab Res"},{"key":"1529_CR11","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","volume":"106","author":"KM Hoeger","year":"2021","unstructured":"Hoeger\u00a0KM, Dokras\u00a0A, Piltonen\u00a0T (2021) Update on PCOS: consequences, challenges, and guiding treatment. J\u00a0Clin Endocrinol Metab 106:e1071\u2013e1083","journal-title":"J Clin Endocrinol Metab"},{"key":"1529_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/cen.13968","volume":"90","author":"Z Javed","year":"2019","unstructured":"Javed\u00a0Z, Papageorgiou\u00a0M, Deshmukh\u00a0H, Rigby\u00a0AS, Qamar\u00a0U, Abbas\u00a0J, Khan\u00a0AY, Kilpatrick\u00a0ES, Atkin\u00a0SL, Sathyapalan\u00a0T (2019) Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. Clin Endocrinol (Oxf) 90:805\u2013813","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1529_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(00)02770-7","volume":"356","author":"W Jeffcoate","year":"2000","unstructured":"Jeffcoate\u00a0W, Kong\u00a0MF (2000) Diabete des femmes a\u00a0barbe: a\u00a0classic paper reread. Lancet 356:1183\u20131185","journal-title":"Lancet"},{"key":"1529_CR14","doi-asserted-by":"publisher","unstructured":"Jensterle M, Herman R, Janez A (2022) Therapeutic potential of glucagon-like peptide\u20111 agonists in polycystic ovary syndrome: from current clinical evidence to future perspectives. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10081989","DOI":"10.3390\/biomedicines10081989"},{"key":"1529_CR15","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/S2213-8587(22)00163-2","volume":"10","author":"AE Joham","year":"2022","unstructured":"Joham\u00a0AE, Norman\u00a0RJ, Stener-Victorin\u00a0E, Legro\u00a0RS, Franks\u00a0S, Moran\u00a0LJ, Boyle\u00a0J, Teede\u00a0HJ (2022) Polycystic ovary syndrome. Lancet Diabetes Endocrinol 10:668\u2013680","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1529_CR16","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2337\/dc18-1738","volume":"42","author":"NS Kakoly","year":"2019","unstructured":"Kakoly\u00a0NS, Earnest\u00a0A, Teede\u00a0HJ, Moran\u00a0LJ, Joham\u00a0AE (2019) The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome. Diabetes Care 42:560\u2013567","journal-title":"Diabetes Care"},{"key":"1529_CR17","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/humupd\/dmy007","volume":"24","author":"NS Kakoly","year":"2018","unstructured":"Kakoly\u00a0NS, Khomami\u00a0MB, Joham\u00a0AE, Cooray\u00a0SD, Misso\u00a0ML, Norman\u00a0RJ, Harrison\u00a0CL, Ranasinha\u00a0S, Teede\u00a0HJ, Moran\u00a0LJ (2018) Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a\u00a0systematic review and meta-regression. Hum Reprod Update 24:455\u2013467","journal-title":"Hum Reprod Update"},{"key":"1529_CR18","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3109\/09513590.2015.1006188","volume":"31","author":"MG Kaya","year":"2015","unstructured":"Kaya\u00a0MG, Yildirim\u00a0S, Calapkorur\u00a0B, Akpek\u00a0M, Unluhizarci\u00a0K, Kelestimur\u00a0F (2015) Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. Gynecol Endocrinol 31:401\u2013405","journal-title":"Gynecol Endocrinol"},{"key":"1529_CR19","doi-asserted-by":"publisher","first-page":"e1002542","DOI":"10.1371\/journal.pmed.1002542","volume":"15","author":"B Kumarendran","year":"2018","unstructured":"Kumarendran\u00a0B, O\u2019Reilly\u00a0MW, Manolopoulos\u00a0KN, Toulis\u00a0KA, Gokhale\u00a0KM, Sitch\u00a0AJ, Wijeyaratne\u00a0CN, Coomarasamy\u00a0A, Arlt\u00a0W, Nirantharakumar\u00a0K (2018) Polycystic ovary syndrome, androgen excess, and the risk of nonalcoholic fatty liver disease in women: A longitudinal study based on a\u00a0United Kingdom primary care database. PLoS Med 15:e1002542","journal-title":"PLoS Med"},{"key":"1529_CR20","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1210\/jc.2015-2778","volume":"100","author":"RS Legro","year":"2015","unstructured":"Legro\u00a0RS, Dodson\u00a0WC, Kris-Etherton\u00a0PM, Kunselman\u00a0AR, Stetter\u00a0CM, Williams\u00a0NI, Gnatuk\u00a0CL, Estes\u00a0SJ, Fleming\u00a0J, Allison\u00a0KC, Sarwer\u00a0DB, Coutifaris\u00a0C, Dokras\u00a0A (2015) Randomized controlled trial of preconception interventions in infertile women with polycystic ovary syndrome. J\u00a0Clin Endocrinol Metab 100:4048\u20134058","journal-title":"J Clin Endocrinol Metab"},{"key":"1529_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/obr.12762","volume":"20","author":"SS Lim","year":"2019","unstructured":"Lim\u00a0SS, Kakoly\u00a0NS, Tan\u00a0JWJ, Fitzgerald\u00a0G, Bahri Khomami\u00a0M, Joham\u00a0AE, Cooray\u00a0SD, Misso\u00a0ML, Norman\u00a0RJ, Harrison\u00a0CL, Ranasinha\u00a0S, Teede\u00a0HJ, Moran\u00a0LJ (2019) Metabolic syndrome in polycystic ovary syndrome: a\u00a0systematic review, meta-analysis and meta-regression. Obes Rev 20:339\u2013352","journal-title":"Obes Rev"},{"key":"1529_CR22","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1093\/humrep\/deaa099","volume":"35","author":"G Mills","year":"2020","unstructured":"Mills\u00a0G, Badeghiesh\u00a0A, Suarthana\u00a0E, Baghlaf\u00a0H, Dahan\u00a0MH (2020) Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a\u00a0population-based study on 9.1\u00a0million pregnancies. Hum Reprod 35:1666\u20131674","journal-title":"Hum Reprod"},{"key":"1529_CR23","doi-asserted-by":"publisher","first-page":"E628","DOI":"10.1210\/jc.2012-3908","volume":"98","author":"P Moghetti","year":"2013","unstructured":"Moghetti\u00a0P, Tosi\u00a0F, Bonin\u00a0C, Di Sarra\u00a0D, Fiers\u00a0T, Kaufman\u00a0JM, Giagulli\u00a0VA, Signori\u00a0C, Zambotti\u00a0F, Dall\u2019Alda\u00a0M, Spiazzi\u00a0G, Zanolin\u00a0ME, Bonora\u00a0E (2013) Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J\u00a0Clin Endocrinol Metab 98:E628\u2013E637","journal-title":"J Clin Endocrinol Metab"},{"key":"1529_CR24","first-page":"CD003053","volume":"11","author":"LC Morley","year":"2017","unstructured":"Morley\u00a0LC, Tang\u00a0T, Yasmin\u00a0E, Norman\u00a0RJ, Balen\u00a0AH (2017) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D\u2011chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 11:CD3053","journal-title":"Cochrane Database Syst Rev"},{"key":"1529_CR25","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2213-8587(16)30217-0","volume":"4","author":"L Poston","year":"2016","unstructured":"Poston\u00a0L, Caleyachetty\u00a0R, Cnattingius\u00a0S, Corvalan\u00a0C, Uauy\u00a0R, Herring\u00a0S, Gillman\u00a0MW (2016) Preconceptional and maternal obesity: epidemiology and health consequences. Lancet Diabetes Endocrinol 4:1025\u20131036","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1529_CR26","doi-asserted-by":"publisher","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","volume":"143","author":"TM Powell-Wiley","year":"2021","unstructured":"Powell-Wiley\u00a0TM, Poirier\u00a0P, Burke\u00a0LE, Despres\u00a0JP, Gordon-Larsen\u00a0P, Lavie\u00a0CJ, Lear\u00a0SA, Ndumele\u00a0CE, Neeland\u00a0IJ, Sanders\u00a0P, St-Onge\u00a0MP (2021) Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 143:e984\u2013e1010","journal-title":"Circulation"},{"key":"1529_CR27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","volume":"19","author":"Rotterdam EA-SPcwg","year":"2004","unstructured":"Rotterdam EA-SPcwg (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41\u201347","journal-title":"Hum Reprod"},{"key":"1529_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1210\/jc.2009-1834","volume":"95","author":"S Tan","year":"2010","unstructured":"Tan\u00a0S, Bechmann\u00a0LP, Benson\u00a0S, Dietz\u00a0T, Eichner\u00a0S, Hahn\u00a0S, Janssen\u00a0OE, Lahner\u00a0H, Gerken\u00a0G, Mann\u00a0K, Canbay\u00a0A (2010) Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J\u00a0Clin Endocrinol Metab 95:343\u2013348","journal-title":"J Clin Endocrinol Metab"},{"key":"1529_CR29","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/dom.14495","volume":"23","author":"S Tan","year":"2021","unstructured":"Tan\u00a0S, Ignatenko\u00a0S, Wagner\u00a0F, Dokras\u00a0A, Seufert\u00a0J, Zwanziger\u00a0D, Dunschen\u00a0K, Zakaria\u00a0M, Huseinovic\u00a0N, Basson\u00a0CT, Mahling\u00a0P, Fuhrer\u00a0D, Hinder\u00a0M (2021) Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. Diabetes Obes Metab 23:2595\u20132599","journal-title":"Diabetes Obes Metab"},{"key":"1529_CR30","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2350-11-12","volume":"11","author":"S Tan","year":"2010","unstructured":"Tan\u00a0S, Scherag\u00a0A, Janssen\u00a0OE, Hahn\u00a0S, Lahner\u00a0H, Dietz\u00a0T, Scherag\u00a0S, Grallert\u00a0H, Vogel\u00a0CI, Kimmig\u00a0R, Illig\u00a0T, Mann\u00a0K, Hebebrand\u00a0J, Hinney\u00a0A (2010) Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet 11:12","journal-title":"BMC Med Genet"},{"key":"1529_CR31","doi-asserted-by":"publisher","first-page":"254169","DOI":"10.1155\/2015\/254169","volume":"2015","author":"S Tan","year":"2015","unstructured":"Tan\u00a0S, Vollmar\u00a0N, Benson\u00a0S, Sowa\u00a0JP, Bechmann\u00a0LP, Gerken\u00a0G, Fuhrer\u00a0D, Canbay\u00a0A (2015) Liver injury indicating fatty liver but not serologic NASH marker improves under metformin treatment in polycystic ovary syndrome. Int J Endocrinol 2015:254169","journal-title":"Int J Endocrinol"},{"key":"1529_CR32","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/humrep\/dey256","volume":"33","author":"HJ Teede","year":"2018","unstructured":"Teede\u00a0HJ, Misso\u00a0ML, Costello\u00a0MF, Dokras\u00a0A, Laven\u00a0J, Moran\u00a0L, Piltonen\u00a0T, Norman\u00a0RJ, International\u00a0PN (2018) Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod 33:1602\u20131618","journal-title":"Hum Reprod"},{"key":"1529_CR33","doi-asserted-by":"publisher","first-page":"e1003679","DOI":"10.1371\/journal.pmed.1003679","volume":"19","author":"SS Venkatesh","year":"2022","unstructured":"Venkatesh\u00a0SS, Ferreira\u00a0T, Benonisdottir\u00a0S, Rahmioglu\u00a0N, Becker\u00a0CM, Granne\u00a0I, Zondervan\u00a0KT, Holmes\u00a0MV, Lindgren\u00a0CM, Wittemans\u00a0LBL (2022) Obesity and risk of female reproductive conditions: a mendelian randomisation study. PLoS Med 19:e1003679","journal-title":"PLoS Med"},{"key":"1529_CR34","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.fertnstert.2010.12.027","volume":"95","author":"RA Wild","year":"2011","unstructured":"Wild\u00a0RA, Rizzo\u00a0M, Clifton\u00a0S, Carmina\u00a0E (2011) Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95:1073\u20131079","journal-title":"Fertil Steril"},{"key":"1529_CR35","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1007\/s00125-012-2638-6","volume":"55","author":"P Wojciechowski","year":"2012","unstructured":"Wojciechowski\u00a0P, Lipowska\u00a0A, Rys\u00a0P, Ewens\u00a0KG, Franks\u00a0S, Tan\u00a0S, Lerchbaum\u00a0E, Vcelak\u00a0J, Attaoua\u00a0R, Straczkowski\u00a0M, Azziz\u00a0R, Barber\u00a0TM, Hinney\u00a0A, Obermayer-Pietsch\u00a0B, Lukasova\u00a0P, Bendlova\u00a0B, Grigorescu\u00a0F, Kowalska\u00a0I, Goodarzi\u00a0MO, Consortium\u00a0G, Strauss\u00a0JF 3rd, McCarthy\u00a0MI, Malecki\u00a0MT (2012) Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a\u00a0systematic review and meta-analysis. Diabetologia 55:2636\u20132645","journal-title":"Diabetologia"},{"key":"1529_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/978-3-642-69928-3_6","volume":"8","author":"F Wong-Staal","year":"1985","unstructured":"Wong-Staal\u00a0F (1985) The oncogene and its potential role in carcinogenesis. Arch Toxicol Suppl 8:61\u201372","journal-title":"Arch Toxicol Suppl"},{"key":"1529_CR37","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s40265-022-01779-z","volume":"82","author":"S Yang","year":"2022","unstructured":"Yang\u00a0S, Zhao\u00a0L, He\u00a0W, Mi\u00a0Y (2022) The effect of oral antidiabetic drugs on improving the endocrine and metabolic states in women with polycystic ovary syndrome: a systematic review and network meta-analysis. Drugs 82:1469\u20131480","journal-title":"Drugs"},{"key":"1529_CR38","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1210\/jc.2007-1834","volume":"93","author":"BO Yildiz","year":"2008","unstructured":"Yildiz\u00a0BO, Knochenhauer\u00a0ES, Azziz\u00a0R (2008) Impact of obesity on the risk for polycystic ovary syndrome. J\u00a0Clin Endocrinol Metab 93:162\u2013168","journal-title":"J Clin Endocrinol Metab"},{"key":"1529_CR39","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.tem.2007.07.003","volume":"18","author":"HF Escobar-Morreale","year":"2007","unstructured":"Escobar-Morreale\u00a0HF, San Millan\u00a0JL (2007) Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 18:266\u2013272","journal-title":"Trends Endocrinol Metab"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01529-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01529-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01529-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T05:04:04Z","timestamp":1687323844000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01529-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,8]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1529"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01529-7","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,8]]},"assertion":[{"value":"3 May 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Tan erkl\u00e4rt, von Novartis eine F\u00f6rderung zur Durchf\u00fchrung von Studien erhalten zu haben. L.\u00a0van Baal gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}